Etherna – Our Company
Our Management Team
Engineering the Future of mRNA
Steven Powell
CEO
Steven Powell
Steven has acquired broad experience in several life-science sectors in R&D, corporate finance and commercial roles. He started his career with Beecham Pharmaceuticals (now GSK) and subsequently held senior roles with both public and private biotechnology and healthcare companies in Europe and North America. He was also a partner with a European venture capital fund.
Bernard Sagaert
Senior VP, COO
Bernard Sagaert
Bernard is an industrial pharmacist and licensed Qualified Person with extensive and broad experience in the Pharmaceutical industry internationally in large, medium sized and small companies.
Mathieu Lane
CFO and President of eTheRNA Inc.
Mathieu Lane
Mathieu has spent over 15 years in healthcare investment banking in New York, working on a broad range of financing and strategic transactions for both large pharmaceutical and emerging biopharma companies. He was most recently at Guggenheim Securities and at Bear Stearns prior to that. An organic chemist by training, he has also worked in lipid-based gene therapy research at Genzyme and in venture capital at SR One.
Ulrich Platte
Senior VP Europe and Asia
Ulrich Platte
Ulrich has over 20 years experience in a number of different industrial sectors including the life science, medical device and pharmaceutical sectors. He has held senior positions in financial management roles, including previous CFO roles.
Michael Mulqueen
VP Business Development
Michael Mulqueen
Michael started his career with Roche as part of the business development department with a strong focus on in-licensing and alliance management. He left Roche to set up Synosia Therapeutics AG. From this point on, he worked with a number of European biotech companies with a focus on out-licensing and partnering. Latterly, he was VP for BD and Licensing with Silence Therapeutics in the RNAi field.
Volker Germaschewski
Senior VP R&D
Volker Germaschewski
Volker joins from Kymab Ltd. (Cambridge, UK) where, over 10 years, he was initially Senior Director Discovery and subsequently Vice President of Haematology. Prior to that he held several positions in Biopharm R&D at GlaxoSmithKline.
Stefaan De Koker
VP Discovery
Stefaan De Koker
Stefaan is Principal Scientist with over 15 years of research experience in immunology, immuno-oncology, vaccine design and nucleic acid delivery. He has a publication track record of over >50 publications and is the key author of a number of patents.
Diane Van Hoorick
VP Translational Development
Diane Van Hoorick
Diane is a molecular biophysicist with over 10 years of experience in pharmaceutical R&D; from drug discovery to clinical development. Before joining eTheRNA, Diane held the position of Head of immune oncology project management at Ablynx, Sanofi.
Marina Cools
VP Clinical Development
Marina Cools
Marina is a virologist with over twenty years of experience in pharmaceutical R&D; from drug discovery to late stage clinical development. She has worked with biotech SMEs and large pharmaceutical companies.
Phil Challis
VP Product Development
Phil Challis
Phil has 30 years of experience in the Pharmaceutical and Biotech industry having worked for small SME’s, larger pharmaceutical companies and CDMO’s. He has broad experience in manufacture of biologicals and NCE’s with experience in transfer of processes from R&D, process development through clinical phases and process validation and commercial manufacture.
Dirk Van Broekhoven
VP Corporate Management, General Counsel
Dirk Van Broekhoven
Dirk has more than twenty-five years of experience as legal counsel in the healthcare industry. In addition to his general legal, he has specialized in intellectual property management and corporate development and licensing.
// our company
A Strong
A Strong
Shareholder Base
Since its inception, eTheRNA has raised a total amount of over EUR 58 million in equity investment, including a Series A financing of EUR 24 million announced in 2016 and Series B financing of EUR 34 million announced mid-2020.
Equity Investment Shareholders
- Boehringer Ingelheim
- BNP Paribas Fortis Private Equity
- CGE Healthcare
- Fund+
- LSP
- Novalis LifeSciences LLC
- Omega Funds
- PMV
- Yijing Capital
Founding Shareholders
- Carlo Heirman
- Kris Thielemans
- Progress Pharma
- Sonja Van Meirvenne
- VUB
// our company
Our Board of Directors
eTheRNA is managed by an experienced team of committed biotech professionals.
Who will bring eTheRNA’s mRNA-based TriMix technology to the next level.
Who will bring eTheRNA’s mRNA-based TriMix technology to the next level.
Russel G. Greig
Chairman of the Board
Alexandra Tolia
Representing Fund+
Anne Xie
Yijing Capital
Frank Kalkbrenner
Representing BIV Fund
John de Koning
Representing LSP
Kenneth Wils
Representing PMV
Steven Powell
CEO
Vincent Brichard
External Industry Expert
Vincent Ossipow
Representing Omega Funds
Yijun Chen
CGE Healthcare